High early burden of post-stroke spasticity and persistent treatment gaps in structured follow-up care

BACKGROUND: Post-stroke spasticity (PSS) is a frequent and disabling complication after stroke. Real-world data on the implementation of guideline-recommended antispastic treatment within structured follow-up programs are limited. METHODS: In this prospective cohort study, patients with persistent motor deficits after stroke were followed within a structured post-stroke care program. Spasticity was assessed using the Modified Ashworth Scale (MAS) at predefined follow-up intervals (3 and 12 months after stroke onset). Clinically relevant spasticity was defined as MAS ≥ 2 in at least one joint. Antispastic treatments, including botulinum toxin type A (BoNT-A), were recorded. The implementation gap for BoNT-A was defined as the proportion of patients with a treatment recommendation who had not initiated therapy. RESULTS: Using a cumulative 12-month MAS-based definition among patients with persistent paresis and available follow-up assessments, clinically relevant spasticity was observed in 40/55 patients (72.7%, 95% CI 59-83.9), while 51/55 patients (92.7%, 95% CI 82.4-97.9) showed any increase in muscle tone (MAS > 0). Clinically relevant spasticity was present in 34/53 patients at 3 months (64.2%, 95% CI 49.8-76.9) and in 26/46 patients at 12 months (56.5%, 95% CI 41.1-71.1). Among patients with clinically relevant spasticity, BoNT-A treatment was recommended in 11.8% at 3 months and 26.9% at 12 months, while no patient with a documented recommendation had initiated therapy. CONCLUSIONS: PSS occurs early and affects a substantial proportion of patients with persistent motor deficits after stroke. Despite structured follow-up and systematic screening, implementation of guideline-recommended BoNT-A therapy remained absent in patients with documented treatment recommendations, indicating substantial barriers to evidence-based outpatient spasticity care.

Authors

Institutions

Publication Details

Journal
Neurological Research and Practice
Published
2026-11-18
DOI
https://doi.org/10.1186/s42466-026-00554-9
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

High early burden of post-stroke spasticity and persistent treatment gaps in structured follow-up care

Isabella Stuckart, Hagen B. Huttner, Eyad Altarsha, Timo Siepmann et al.
3 links
Neurological Research and Practice
Botulinum Toxin and Related Neurological Disorders
article

High early burden of post-stroke spasticity and persistent treatment gaps in structured follow-up care

Isabella Stuckart, Hagen B. Huttner, Eyad Altarsha, Timo Siepmann, Daniela Schoene, Jessica Barlinn, Uwe Helbig, Nastasja Pfaff, Simon Winzer, Kristian Barlinn, Lisa Frost
article en

Abstract

BACKGROUND: Post-stroke spasticity (PSS) is a frequent and disabling complication after stroke. Real-world data on the implementation of guideline-recommended antispastic treatment within structured follow-up programs are limited. METHODS: In this prospective cohort study, patients with persistent motor deficits after stroke were followed within a structured post-stroke care program. Spasticity was assessed using the Modified Ashworth Scale (MAS) at predefined follow-up intervals (3 and 12 months after stroke onset). Clinically relevant spasticity was defined as MAS ≥ 2 in at least one joint. Antispastic treatments, including botulinum toxin type A (BoNT-A), were recorded. The implementation gap for BoNT-A was defined as the proportion of patients with a treatment recommendation who had not initiated therapy. RESULTS: Using a cumulative 12-month MAS-based definition among patients with persistent paresis and available follow-up assessments, clinically relevant spasticity was observed in 40/55 patients (72.7%, 95% CI 59-83.9), while 51/55 patients (92.7%, 95% CI 82.4-97.9) showed any increase in muscle tone (MAS > 0). Clinically relevant spasticity was present in 34/53 patients at 3 months (64.2%, 95% CI 49.8-76.9) and in 26/46 patients at 12 months (56.5%, 95% CI 41.1-71.1). Among patients with clinically relevant spasticity, BoNT-A treatment was recommended in 11.8% at 3 months and 26.9% at 12 months, while no patient with a documented recommendation had initiated therapy. CONCLUSIONS: PSS occurs early and affects a substantial proportion of patients with persistent motor deficits after stroke. Despite structured follow-up and systematic screening, implementation of guideline-recommended BoNT-A therapy remained absent in patients with documented treatment recommendations, indicating substantial barriers to evidence-based outpatient spasticity care.

Neurological Research and PracticeVol. 8(1)
University Hospital Carl Gustav Carus (DE), Technische Universität Dresden (DE)
Technische Universität Dresden, Ipsen
Good health and well-being
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon